Updated 7 October 2026. Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist. Depending on the product and jurisdiction, it is approved for type 2 diabetes, chronic weight management and, in the US, moderate-to-severe obstructive sleep apnea in adults with obesity. In August 2026 the FDA also expanded the US cardiovascular indication for Mounjaro in certain adults with type 2 diabetes.
How tirzepatide works
Tirzepatide activates receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These pathways influence glucose-dependent insulin secretion, glucagon regulation, appetite, food intake and body weight. Tirzepatide is a dual agonist; it should not be confused with the investigational triple agonist retatrutide.
Type 2 diabetes evidence
The SURPASS programme evaluated tirzepatide across different stages of type 2 diabetes and against several active comparators. Trials reported substantial average reductions in A1C and body weight, with results depending on baseline characteristics, dose, adherence and comparator.
Mounjaro is approved in the US to improve glycaemic control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise. Age ranges and labels vary in other countries.
Weight-management evidence
The SURMOUNT programme studied tirzepatide in obesity and overweight with weight-related complications. In SURMOUNT-1, adults without diabetes achieved dose-dependent average weight reductions over 72 weeks. Zepbound subsequently received approval for chronic weight management in eligible adults.
Long-term management matters. SURMOUNT-4 showed that participants switched to placebo after initial tirzepatide treatment regained weight on average, while continued treatment maintained and extended weight reduction. In 2026, SURMOUNT-MAINTAIN studied whether a lower maintenance dose could preserve weight reduction after treatment at a maximum tolerated dose. These data support obesity as a chronic condition but do not define the right maintenance strategy for every patient.
Obstructive sleep apnea
In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, together with a reduced-calorie diet and increased physical activity. The approval was based on two randomized 52-week studies involving participants who used positive-airway-pressure therapy and those who were unable or unwilling to use it.
Tirzepatide reduced the apnea-hypopnea index and body weight compared with placebo. It should not be presented as a universal replacement for positive-airway-pressure therapy; assessment and treatment of OSA remain individualized.
Cardiovascular update in 2026
On 28 August 2026, the FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events—cardiovascular death, non-fatal heart attack or non-fatal stroke—in adults with type 2 diabetes at high cardiovascular risk.
The decision was based on SURPASS-CVOT, which enrolled more than 13,000 participants and compared tirzepatide directly with dulaglutide. Tirzepatide met the trial’s non-inferiority objective. The estimated hazard ratio for the first major cardiovascular event was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. This supports the approved risk-reduction claim but does not establish statistical superiority over dulaglutide.
Comparisons with semaglutide
Some trials and real-world studies have compared tirzepatide with semaglutide, but the answer depends on the exact product, dose, population, endpoint and study design. A result from one head-to-head weight-management trial should not be generalized to every diabetes, cardiovascular or safety outcome.
Choosing between prescription medicines requires attention to approved indication, medical history, tolerability, availability and local guidance rather than a single weight-loss percentage.
Safety and labelled precautions
The most common adverse effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation and abdominal discomfort, especially during dose escalation. Labelled warnings and precautions include pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycaemia when combined with insulin or insulin-secretagogue medicines, diabetic-retinopathy complications in susceptible people, severe gastrointestinal reactions and aspiration risk around anaesthesia or deep sedation.
Tirzepatide causes thyroid C-cell tumours in rats; whether this occurs in humans is unknown. Products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnancy, contraception, other medicines and planned procedures require discussion with a qualified clinician.
Product identity and unapproved versions
Mounjaro and Zepbound contain the same active ingredient but have different approved indications and labels. Neither should be confused with compounded, counterfeit or “research” tirzepatide. Products outside regulated supply chains may not match approved medicines in identity, concentration, sterility, formulation or dosing accuracy.
Current status in 2026
Tirzepatide is an approved prescription medicine with indication-specific evidence in type 2 diabetes, obesity, obstructive sleep apnea and selected cardiovascular-risk reduction. Labels and availability vary by country. Research continues in additional populations and outcomes, but ongoing studies should not be described as established indications.
Sources
- FDA: approval of tirzepatide for obstructive sleep apnea
- Eli Lilly: 2026 FDA cardiovascular-risk approval
- ClinicalTrials.gov: SURPASS-CVOT
- ClinicalTrials.gov: SURMOUNT-1
- ClinicalTrials.gov: SURMOUNT-MAINTAIN
This article is for educational reference only and is not medical advice. Prescription tirzepatide should be used only for an approved indication under qualified medical supervision.
